(Q24246913)

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Literature review of the usefulness of repetitive nerve stimulation and single fiber EMG in the electrodiagnostic evaluation of patients with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Reliability testing of the quantitative myasthenia gravis score

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Passive transfer of Lambert-Eaton myasthenic syndrome with IgG from man to mouse depletes the presynaptic membrane active zones

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Calcium-channel antibodies in the Lambert-Eaton syndrome and other paraneoplastic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Short report: 4-Aminopyridine--a new drug tested in the treatment of Eaton-Lambert syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Effects of 4-aminopyridine on neuromuscular transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Novel drug of choice in Eaton-Lambert syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

An improved diagnostic assay for Lambert-Eaton myasthenic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

The Lambert-Eaton myasthenic syndrome. A review of 50 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Guanidine hydrochloride in the Eaton-Lambert syndrome. Electrophysiologic improvement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

The effect of myasthenic syndrome antibody on presynaptic calcium channels in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Long-term follow-up of Lambert-Eaton syndrome treated with intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Low-dose guanidine and pyridostigmine: relatively safe and effective long-term symptomatic therapy in Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Potency of 3,4-Diaminopyridine and 4-aminopyridine on mammalian neuromuscular transmission and the effect of pH changes

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Autoimmune aetiology for myasthenic (Eaton-Lambert) syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Paraneoplastic myasthenic syndrome IgG inhibits 45Ca2+ flux in a human small cell carcinoma line

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Effects of 4-aminopyridine in Eaton Lambert Syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Defects of neuromuscular transmission in syndromes other than myasthenia gravis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Quantal components of end-plate potentials in the myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Antibodies to motor nerve terminals: an electrophysiological study of a human myasthenic syndrome transferred to mouse

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Guanidine treatment and impaired renal function in the Eaton-Lambert syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Treatment with oral 4-aminopyridine in disorders of neuromuscular transmission

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Plasma exchange and immunosuppressive drug treatment in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021

Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert-Eaton myasthenic syndrome

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003279.PUB2

7 January 2021